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Résumé en
anglais
Background Low-dose aspirin reduces the incidence of colorectal cancer and
recurrence of adenomas. Cyclooxygenase-2 (COX-2), one of its main target enzymes,
is reportedly over-expressed in colorectal adenomas.Aim To assess COX-2
expression, in relation to adenoma recurrence and the protective effect of aspirin, in
a large series of colorectal adenomas, recruited from a double-blind randomised
controlled trial comparing recurrences after low-dose aspirin or placebo. Methods
Follow-up colonoscopies were performed after 1 and 4 years to assess adenoma
recurrence. COX-2 expression was assessed by immunohistochemistry for each
adenoma obtained at baseline colonoscopy, separately for epithelium, deep stroma
and overall. Architecture, grade of dysplasia, K-ras mutation, p53 and cyclin D1
expression were studied. Results COX-2 expression could be assessed in 219
adenomas from 136 patients: 128 adenomas (58%) from 59 patients strongly
expressed COX-2. Strong COX-2 expression predominated in adenomas larger than
10 mm (84/129 vs 44/90; p=0.02) and in adenomas showing high-grade dysplasia
(22/29 vs 104/188; p=0.04). Deep stromal but not epithelial initial expression of
COX-2 predicted adenoma recurrence in the whole population (30/72 patients or 42%
strongly expressed deep stromal COX-2 compared with16/64 or 25% without
recurrent adenoma; p=0.04). The protective effect of aspirin was mainly observed in
patients in whom COX-2 initial expression was low (RR for recurrence in patients
taking aspirin with low COX-2 expression: 0.59; 95% CI 0.39 to 0.90; p=0.02). There
was no significant effect of aspirin at the end of the trial. Conclusion Over-expression
of COX-2 was frequent and predominated in large and high-grade dysplasia
adenomas. Deep stromal but not epithelial initial expression of COX-2 predicted
recurrence of adenomas. Aspirin did not act preferentially on patients whose initial
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